从INVICTUS试验到当前的考虑:现在还不是退休维生素K抑制剂的时候!
Akshyaya Pradhan1, Somya Mahalawat1, Marco Alfonso Perrone2
1Department of Cardiology, King George's Medical University, Lucknow 226003, India.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
概括
直接口服抗凝剂 (DOAC) 在风湿性心房动 (AF) 患者中对预防中风的维生素K对抗剂 (VKA) 没有优势. 在INVICTUS研究中,DOACs在有效性或减少出血方面没有任何好处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 前庭动 (AF) 的管理依赖于口服抗凝药来预防中风.
- 直接口服抗凝剂 (DOAC) 与维生素K抗剂 (VKA) 相比具有优势,但被排除在膜心脏病的试验之外.
- 风湿性膜AF,特别是额头肌狭窄症,对抗凝血治疗提出了独特的挑战.
研究的目的:
- 评估DOACs与VKAs相比在风湿性膜AF患者中的疗效和安全性.
- 为了确定DOAC在预防中风和其他血栓栓塞事件方面是否优于VKA,在这个特定的人群中.
主要方法:
- INVICTUS研究是一项大型,多中心,全球随机对照试验 (RCT).
- 患有风湿性膜AF的患者被随机分配给接受Rivaroxaban (DOAC) 或VKA.
- 主要疗效终点包括中风,全身血栓塞,心肌梗塞和死亡. 此外,还评估了出血率.
主要成果:
- 里瓦罗克萨班在主要疗效终点上没有表现出优于VKA的优势.
- 与VKA相比,Rivaroxaban的出血率并没有显著降低.
- 在里瓦洛克萨班组中观察到较高的死亡率和药物停用率.
结论:
- 对于AF并发症中度至严重的额头肌狭窄症或假,VKA仍然是标准的护理.
- 根据INVICTUS研究结果,对患有风湿性膜AF的患者不建议使用DOAC.
- 需要进一步的研究来澄清DOACs和新兴抗凝剂在膜心脏病中的作用.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Renal Failure: Dose Adjustments
64
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
64
Antihypertensive Drugs: Potassium-Sparing Diuretics
455
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
455
Pharmacokinetics: Overview
5.6K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
5.6K


